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Interpretive Summary 3 
New opportunities of cancer prevention through changes in diet regimens can be 4 
developed from the increasing knowledge of food components effects on health. 5 
Consumption of milk and dairy products, as well as lactoferrin enriched food may 6 
prevent the development of breast cancer, by the decrease of cancer cell viability and 7 
proliferation, increase of apoptosis levels and decrease of cancer cell migration.  8 
 9 
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ABSTRACT 24 
The evidence that biologically active food components are key environmental factors 25 
affecting the incidence of many chronic diseases is overwhelming. However,  the full 26 
extent of such components in our diet is unknown, as well as our understanding of their 27 
mechanisms of action.  Beyond their interaction with the gut and intestinal immune 28 
functions, more benefits are being tested for whey proteins such as lactoferrin, namely 29 
as anti-cancer agents. Lactoferrin is an iron-binding protein that has been reported to 30 
inhibit several types of cancer. In the present work, the effects of bovine milk lactoferrin 31 
on human breast cancer HS578T and T47D cells were studied. The cells were either 32 
untreated or submitted to lactoferrin concentrations ranging from 0. 125 to 125 μM. 33 
Lactoferrin decreased 47% and 54% the cell viability of HS578T and T47D, 34 
respectively, and increased apoptosis about twofold for both cell lines. Proliferation 35 
rates decreased between 40.3 and 63.9% for HS578T and T47D, respectively. T47D cell 36 
migration decreased in the presence of the protein. Although the mechanisms of action 37 
have still not been unrevealed, the results gathered in this work suggest that lactoferrin 38 
interferes with some of the most important steps involved in cancer development. 39 
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 43 
INTRODUCTION 44 
 45 
Milk and dairy products have become recognized as functional foods, suggesting 46 
their use has a direct and measurable effect on health outcomes, namely that their 47 
consumption has been related with a reduced risk of numerous cancers (Marshall, 48 
2004). Cancer is the second leading cause of mortality worldwide, with an expected 1.4 49 
million persons being diagnosed with breast cancer in 2010. Hence, this is an 50 
enormously important health risk, and progress leading to enhanced survival is a global 51 
priority (Jemal et al., 2009; Schiff and Osborne, 2005).  52 
Breast cancer, like all the other cancer types, is a result of six essential 53 
alterations in normal cells that represent good targets for treatment; the so-called cancer 54 
hallmarks (Hanahan and Weinberg, 2000). These include the ability to be self-sufficient 55 
in growth signals (tumor cells present reduced dependence on exogenous growth 56 
stimulation); to evade anti-growth signs and apoptosis; to achieve endless replicative 57 
potential; to sustain angiogenesis; to evade tissues, and to form metastasis. Several 58 
strategies have been pursued in the last years in order to hamper the development of 59 
tumors or treat existing ones (Hanahan and Weinberg, 2000).  60 
An increasing interest has been reported on the use of biologically active 61 
substances from food (Ferguson 2009; Gill et al., 2000; Jacobs et al., 2009; McCabe-62 
Sellers et al., 2009; Perdigon et al., 2002; Tsuda et al. 2004). However, the full set of 63 
active components in our diet is unknown and the knowledge on their mechanisms of 64 
action is scarce. Proteins and peptides existing in milk have been reported to be cancer 65 
preventive agents (Korhonen and Pihlanto, 2006; Rodrigues et al., 2009; Tsuda et al., 66 
2000; Wakabayashi et al., 2006), such as lactoferrin (LF), that is also known for its 67 
inhibitory action on cell proliferation, as well as for its anti-inflammatory and 68 
antioxidant abilities (Iigo et al., 2009; Legrand et al., 2005; Pan et al., 2007; Rodrigues 69 
et al., 2009; Tomita et al., 2002; Tsuda et al., 2002, 2010; Ward et al., 2005).  70 
LF is an iron-binding glycoprotein from the transferrin family that can be found 71 
in many different tissues or secretions, such as tears, saliva, blood, secondary granules 72 
of neutrophils and milk (Rodrigues et al., 2009; Pan et al., 2007; Tsuda et al., 2002). In 73 
vivo studies showed that oral administration of bovine LF to rodents significantly 74 
reduces chemically induced tumorigenesis in different organs (breast, esophagus, 75 
tongue, lung, liver, colon and bladder) and inhibits angiogenesis (Iigo et al., 2009; 76 
Tsuda et al., 2002). It has been demonstrated that more than 60% of administrated 77 
bovine LF survived passage through the adult human stomach and entered the small 78 
intestine in an intact form (Troost et al., 2001). Intact and partly intact bovine LF are 79 
likely to exert various physiological effects in the digestive tract. Moreover, 80 
subcutaneously administration of LF inhibited the growth of implanted solid tumors and 81 
exerted preventive effects on metastasis (Bezault et al., 1994).  82 
These activities of LF have been attributed to its immunomodulatory potential 83 
and ability to activate T and NK cells (Bezault et al., 1994; Damiens et al., 1999). LF is 84 
able to limit the growth of tumor cells and it was shown that addition of exogenous LF 85 
to MDA-MB-231 breast cancer cell lines culture media induced the cell cycle arrest at 86 
the G1/S transition (Damiens et al., 1999). Also, LF was found to induce growth arrest 87 
and nuclear accumulation of Smad-2 in HeLa cells (Zemann et al., 2010). According to 88 
Babina and coworkers (2005), LF possesses DNase activity and; is cytotoxic, 89 
suppressing the growth of several human and mouse cell lines. Recent studies 90 
demonstrated that LF has an estrogen element of response (ERE) (Teng, 2006) that 91 
confers the protein the ability to interfere with the genetic expression of several 92 
molecules that are vital for cell survival. Furthermore, LF was found to induce apoptosis 93 
in several human cell lines, as for example A459 lung cells, CaCO-2 intestine cells and 94 
HTB9 kidney cells (Hakansson et al., 1995), and to inhibit Akt activation and modulate 95 
its downstream proteins phosphorylation in apoptosis of SGC-7901 human stomach 96 
cancer cells (Xu et al., 2010). Moreover, LF was effective against melanoma cells (Pan 97 
et al., 2007), decreasing the proliferation rates and increasing apoptosis levels. Xiao and 98 
coworkers (2004) also reported LF’s inhibitory effects on head and neck cancer cells, 99 
down-regulating G1 cyclin-dependent kinases, and therefore influencing the cell cycle. 100 
Finally, LF has been reported to suppress cell-induced angiogenesis in mice, and to 101 
increase the IL-18 production (Xiao et al., 2004).  102 
Knowledge on the effect of diet components on health will put forward new 103 
opportunities for cancer prevention through profound alterations in the diet regimens. 104 
Over time, small but recurrent doses of bioactive proteins may prevent the carcinogenic 105 
process by decreasing the rate of cell proliferation and growth of cancer cells. In the 106 
current work, the effect of a range of LF concentrations at different exposure times on 107 
cell viability, proliferation, apoptosis and migration using two model human breast 108 
cancer cell lines, HS578S and T47D, was studied. The rationale of using two cell lines 109 
is due to their differences in the estrogen receptor. The cells lacking the estrogen 110 
receptor (e.g. HS578T) usually correspond to more aggressive type of tumors for which the 111 
existent therapy is not very efficient. Therefore, for these type cells, if LF shows an effect it 112 
would represent an important scientific advance. On the other hand, for cells that possess the 113 
estrogen receptor (e.g. T47D), if an effect is proved for LF, then a combination with 114 
estrogen could be further explored for breast cancer therapeutics.  115 
 116 
MATERIALS AND METHODS 117 
 118 
Lactoferrin 119 
Lactoferrin (LF) (Sigma-Aldrich Co., St. Louis, MO) was dissolved in phosphate saline 120 
buffer (PBS) (PBS: 1g/L NaCl, 0.2g/L KCl, 0.24g/L Na2HPO4.2H20, 1.805g/L 121 
KH2PO4, pH 7.4) in order to obtain different protein solution concentrations (0.125, 122 
6.25, 12.5 and 125 μM). All LF solutions were passed through a 0.2-μm filter prior to 123 
use, and stored at 4ºC. 124 
 125 
Breast Cancer Cell Lines 126 
Breast cancer cell lines, HS578T and T47D, were kindly provided by IPATIMUP 127 
(Portugal). The HS578T cell strain was derived from a carcinoma of the breast and is 128 
negative for estrogen receptor (ER-). The T47D line was isolated from a pleural 129 
effusion obtained from a 54 year old female patient with an infiltrating ductal carcinoma 130 
of the breast and is positive for estrogen receptor (ER+). The cells were maintained in 131 
an incubator with a 5% CO2 atmosphere and at 37ºC. The culture medium used was the 132 
Dulbecco’s modified Eagle medium (DMEM) (GIBCO®, Invitrogen, Barcelona, 133 
Spain) supplemented with 10% of Fetal Bovine Serum (FBS) (GIBCO®, Invitrogen, 134 
Barcelona, Spain) and 1% of penicillin/streptomycin (Invitrogen, Barcelona, Spain).  135 
 136 
Cell Viability 137 
Two distinct methods were used to evaluate the cell viability to LF exposure as 138 
described below.  139 
 140 
Trypan blue method 141 
Cells were grown in 6-well plates until a concentration of 1×105 cells per well was 142 
achieved. Adequate volumes of the previously prepared LF solutions were added to 143 
each well, in order to obtain the required LF concentrations (0.125, 6.25, 12.5 and 125 144 
μM). Additionally, control wells were included consisting of DMEM medium and PBS 145 
(no LF added). The plates were incubated for 24, 48 and 72 hours. Subsequently, the 146 
supernatant of each well was collected to a falcon tube. The adhered cells were washed 147 
with PBS, trypsinized, and then collected to the respective falcon. All falcons were 148 
centrifuged (700 x g, 5 minutes) and the supernatant was discharged. The remaining 149 
pellet was resuspensed in 100 μl of PBS. The collected cell volumes were diluted 1:1 150 
with Trypan Blue (TB) (Sigma-Aldrich Co., St. Louis, MO), and the viable and non-151 
viable cells were counted in a Neubauer chamber, using an inverted optical microscope 152 
equipped with a 20X objective. The results are expressed as percentage of viable cells 153 
as compared to the control and represent an average of 3 independent cultures with 8 154 
wells per concentration in each experiment. 155 
 156 
MTS method 157 
The cell viability to LF exposure was also determined using the MTS (3-(4,5-158 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 159 
method. A commercial kit was used according to the manufacturer instructions 160 
(Promega, PROM G35800001, Lisbon, Portugal). In these experiments, 100 μl of cell 161 
suspension was added to each well of a 96-well plate. Additionally, control wells were 162 
included consisting of DMEM medium and PBS. When a cell concentration of 1×105 163 
cells/ml was obtained, adequate volumes of LF solutions were added to the wells and 164 
incubated for different exposure times (24, 48 and 72 hours). Afterwards, 20 μl of the 165 
CellTitter 96 AQueous One Solution Cell Proliferation Assay reagent (MTS) was added 166 
to each well and left in the incubator (37ºC, 5% CO2) for 3 hours after which the cell 167 
viability was quantified by recording the absorbance at 490 nm. The results are 168 
expressed as percentage of viable cells compared to the control and represent an average 169 
of 3 independent cultures with 8 wells per concentration in each experiment.  170 
 171 
 172 
Apoptosis 173 
The effect of different LF concentrations (0.125, 6.25, 12.5 and 125 μM) and exposure 174 
times (24, 48 and 72 h) in cell apoptosis was accessed using a commercial kit (Promega, 175 
PROM G 8091, Lisbon, Portugal) with the same experimental setup as described above. 176 
After exposing the cells, in a concentration of 1×104 cells/ml, to LF (37ºC, 5% CO2), 177 
100 μl of Caspase-Glo 3/7 reagent was added to the wells, and after 3 hours standing at 178 
room temperature and in the dark, the apoptosis levels were determined by 179 
luminescence recording. The average blank value (DMEM medium alone) was 2845 180 
Relative Luminescence Units (RLU) and 642 RLU for the experiments conducted with 181 
T47D and HS578T, respectively. The blank value was subtracted from all the other 182 
values. The luminescence of the cells in medium (control) lay above this value and is 183 
given by 0 μM LF. The results represent an average of 3 independent cultures with 8 184 
wells per concentration in each experiment. 185 
 186 
Cell Proliferation 187 
Cell proliferation was determined using the bromodeoxyuridine (5-bromo-2-188 
deoxyuridine, BrdU) (Sigma-Aldrich Co., St. Louis, MO) assay. Briefly, a lamella was 189 
placed in each well of a 24-well plate and cells were grown until a cell concentration of 190 
1×105 cells per well was achieved. These experiments were conducted for 12.5 μM LF. 191 
After 48 h of exposure to LF, 50μl of BrdU per ml of culture medium was added to each 192 
well and the plates were incubated (37ºC, 5% CO2) for 3 hours. Afterwards, the cells 193 
were washed with PBS and left at 4ºC in 1ml of paraformaldeid 1% w/v (prepared in 194 
PBS). Subsequently, the fixed cells were treated with HCl 2M at room temperature for 195 
30 minutes. Next, the lamellas were washed with PBS-0.5% Tween20-0.05% bovine 196 
serum albumin (BSA), and incubated with anti-BrdU (mouse) (DAKO Denmark, 197 
Denmark) at a 1:1 dilution with PBS-0.5% Tween20-0.05% BSA. After 1 h, lamellas 198 
were washed twice with PBS-0.5% Tween20-0.05% BSA, and subsequently incubated 199 
with anti-mouse Ig fluorescein isothiocyanate (FITC) (DAKO Denmark, Denmark) at a 200 
1:100 dilution in PBS-0.5% Tween20-0.05% BSA for 30 minutes. Finally, the lamellas 201 
were washed with PBS-0.5% Tween20-0.05% BSA. The nuclei were counted in a 202 
fluorescence microscope (Zeiss HBO-50) using a 40X magnification. The total number 203 
of nuclei was marked with 4',6-diamidino-2-phenylindole (DAPI) (blue) and the ones in 204 
proliferation were marked with FITC (green). Proliferation rates were determined as the 205 
percentage ratio between the number of nuclei in proliferation and total number of 206 
nuclei. The results represent an average of 3 independent cultures and 10 measures for 207 
each culture. 208 
 209 
Migration 210 
A suspension containing 1×105 cells was left to grow in 6-well plates, until 90% 211 
confluence was achieved. Next, adhered cells were washed twice with PBS. Afterwards, 212 
a wound was inflicted in the center of each well, with the help of a needle, and 3 spots 213 
were marked on the wound as reference points. Then, fresh DMEM medium was added 214 
to the wells, and also the adequate volume of LF solution to obtain a 12.5 μM 215 
concentration. During the 48 h of exposure, pictures were taken at the pre-defined 216 
measuring spots using an inverted microscope (Nikon Diaphot 300, Sony, Portugal) 217 
equipped with a 20X objective. The images were captured by a video camera (Sony 218 
CCD, Sony, Portugal) and processed using the Image Pro-Plus® version 7.0 software 219 
(Media Cybernetics, Bethesda, MD) which allowed the measurement of the distance (in 220 
micrometers (μm)) over time between the front cells in each edge of the wound. These 221 
distances correspond to an average of 3 independent cultures and 9 measures for each 222 
culture. 223 
 224 
Statistical Analysis 225 
Two-tailed unpaired Student’s t-test was used for the statistical evaluation of significant 226 
differences among the tested LF concentrations and exposure times as compared to the 227 
control. Statistical analyses were performed in Microsoft Office Excel 2007 (Seattle, 228 
WA). 229 
 230 
RESULTS 231 
 232 
Cell Viability 233 
Trypan blue method 234 
The trypan blue (TB) method enables distinguishing viable cells from dead cells, since 235 
dead cells are permeable to the dye and will be colored blue. The results obtained are 236 
compiled in Table 1. A decrease over 50% in the number of viable cells was obtained 237 
for increasing LF concentrations and exposure times, for both cell lines studied. Based 238 
on these experiments, 12.5 μM LF was found to be effective in decreasing T47D cell 239 
viability as compared to the control (set at 100%) between 28 and 54%, depending on 240 
the exposure time. The differences obtained for the range of LF concentrations studied, 241 
as compared to the control, were found to be statistically significant, except for 0.125 242 
μM. Furthermore, the p-values obtained when comparing the different exposure times, 243 
namely 24 and 48 h, 48 and 72 h, 24 and 72 h, were 0.06, 0.08 and 0.05, respectively. 244 
For the HS578T cell line, the conditions that promoted a more pronounced decrease of 245 
cell viability were 72 h exposure to 125 μM LF. Nevertheless, at this exposure time and 246 
LF concentration, cellular lysis was observed (data not shown). Comparing to the 247 
control, 12.5 μM LF decreased HS578T cell viability between 18 and 47%, depending 248 
on the exposure time. The differences obtained for all the LF concentrations studied 249 
were found to be statistically significant. Also, comparing the different exposure times, 250 
the differences obtained between 24 and 48 h were not statistically significant (p-value 251 
= 0.14), while the p-values obtained for 48 and 72 h, and 24 and 72 h comparisons were 252 
0.02 and 0.03, respectively.  253 
 254 
MTS method 255 
The MTS assay is assumed to reflect cell number and is used to determine exposure-256 
response relationships. Table 1 presents the results obtained in the MTS assays. 257 
Although slightly higher reductions on cell viability were found with this method, 258 
especially for 72 h, the tendencies were similar, thus these results were found to be in 259 
agreement with the ones obtained with the TB dye method. Statistical significance was 260 
found for the comparisons between the different exposure times and the different LF 261 
concentrations used.  262 
 263 
Apoptosis 264 
LF influence in apoptosis was assessed by measuring caspase 3 and 7 activities, since 265 
these are the effectors of the apoptosis machinery. LF increasing concentrations were 266 
found to increase such activities for both cell lines, as can be observed in Fig. 1.  267 
Generally, it was found that for a 72 h exposure a decrease in apoptosis occurs. This 268 
result coincides with the cellular lysis observed in the cell viability assays as described 269 
above. Although cell death was higher for a 72 h exposure to LF, necrosis was found to 270 
be the principal cellular death process occurring for this exposure time. For both cell 271 
lines, the caspases 3/7 activity increased about 1.5-2 times for the lower LF 272 
concentrations studied (except for the concentration 0.125 μM LF in the HS578T 273 
assays), being the differences observed, as compared to the control, statistically 274 
significant. An increase of about 3-5 times in the apoptotic levels was obtained in the 275 
experiments conducted with 125 μM LF. It is important to notice that the differences 276 
observed between the different exposure times were in most of the cases not statistically 277 
significant.  278 
 279 
 Cell Proliferation 280 
Based on the results from MTT, TB and apoptosis assays, a 48 h exposure to 12.5 μM 281 
LF was chosen for the cell proliferation experiments. The effect of LF on cell 282 
proliferation was studied using BrdU, a synthetic thymidine analogue that binds to new-283 
formed DNA in S-phase, thus allowing the determination of the nuclei in proliferation. 284 
As expected from the previous results, LF was found to decrease the proliferation rates 285 
for both cell lines (Fig. 2). Proliferation rate decreases of 35.5% and 52.5% were 286 
obtained for HS578T and T47D, respectively. The differences observed for the 287 
proliferation rates as compared to the control experiments were found to be statistically 288 
significant for both cell lines (p<0.005 for HS578T and p<0.0005 for T47D).  289 
 290 
Migration 291 
The LF concentration and exposure time used in the migration experiments were the 292 
same as the ones used to study cell proliferation. LF was found to decrease the 293 
migration of both cell lines used (Fig. 3 and Fig. 4) being this effect more pronounced 294 
for T47D. From the statistical analysis, the differences observed for HS578T cells 295 
treated and untreated were not significant (p = 0.116). Nevertheless, the differences 296 
observed for T47D were statistically significant (p = 0.001). The distance (μm) between 297 
the front cells in each edge of the wound was higher for the cells exposed to 12.5 μM 298 
LF during 48 h, as compared to the control (with no LF added).  299 
 300 
DISCUSSION 301 
 302 
The role of milk proteins and peptides as physiologically active factors in the diet is 303 
being increasingly acknowledged (Marshall, 2004). Environmental factors, such as food 304 
and physical activity, have an important influence on the risk of cancer, thus delayed 305 
cancer development may be obtained by changing diet regimens. A large amount of data 306 
regarding the bioactivity of food components have been obtained using cell lines, and 307 
an important question regarding much of this work is the relevance of the 308 
concentrations used (Petricoin and Liotta, 2003).  309 
In the current work, the influence of LF on cell viability for both cell lines was 310 
studied using two complementary tests, namely the TB dye method and the bio-311 
reduction of the MTS reagent (Table 1). Some cytotoxicity assays allow the immediate 312 
interpretation of the results, such as the incorporation of a dye by dead cells, release of 313 
51Cr or fluorescein from pre-labeled cells. These assays are viability assays and intend 314 
to predict survival and not directly assessing it, since they are good for identifying dead 315 
cells but can overestimate survival in the long term. Most of these assays involve the 316 
cell membrane rupture and cell death. Cell viability is a measure of the metabolic status 317 
of a population and gives an indication of its growth potential. One of the simplest 318 
methods to evaluate cell viability is the dye exclusion approach, indicating the cellular 319 
membrane capacity to exclude a dye. The most commonly used dye is TB, and the 320 
method is based on the concept that viable cells do not absorb certain dyes while dead 321 
cells are permeable to them. Nevertheless, this method presents some disadvantages, 322 
such as also dying soluble proteins; causing stress to the cells, as well as being 323 
influenced by the presence of serum. Therefore, in this work a complementary test for 324 
assessing cell viability was included. The results obtained showed a decrease over 50% 325 
in the number of viable cells for increasing LF concentrations and exposure times, for 326 
both cell lines studied. Although the results pointed to 72 hours of exposure to 125 μM 327 
LF to be the most effective conditions regarding a decrease in cell viability, at these 328 
conditions cellular lysis was observed. For that reason, and since cellular lysis is 329 
frequently associated with necrosis, such information was taken into consideration for 330 
the choice of the conditions to use (12.5 μM LF was fixed at 48 h) in the following 331 
experiments (proliferation and migration). Once necrosis occurs, the cellular contempt 332 
is spilled into the surrounding tissues, causing inflammation and contamination of the 333 
neighbor cells with carcinogenic products. Therefore, the occurrence of necrosis is a 334 
nonfavorable factor when the goal is treating cancer (Werner et al., 2005).  335 
The results obtained in these experiments are in accordance with data previously 336 
reported for LF effects on other human cancer cell lines (Hakansson et al., 1995; Tsuda 337 
et al., 2004; Xiao et al., 2004). As described above, there are other viability assays, such 338 
as the bio-reduction of the MTS reagent, that measure the metabolic events occurring in 339 
the cell, allowing a more precise quantification since they are more sensitive. These 340 
reductions take place only when reductase enzymes are active, and therefore conversion 341 
is often used as a measure of viable cells. However, these colorimetric assays also 342 
present disadvantages regarding interferences from the culture medium, reversible 343 
metabolic inhibitions and different colorimetric responses for different types of cells. 344 
Also, it is important to keep in mind that other viability tests sometimes give completely 345 
different results, as many different conditions can increase or decrease metabolic 346 
activity. Changes in metabolic activity can give large changes in MTS results while the 347 
number of viable cells is constant. When the amount of purple formazan produced by 348 
cells treated with an agent, such as LF, is compared with the amount of formazan 349 
produced by untreated control cells, the effectiveness of the agent causing death, or 350 
changing metabolism of cells, can be deduced through a dose-response curve. Results 351 
gathered from these experiments were similar to the ones obtained with the TB method. 352 
Furthermore, it is important to notice that, although the higher LF concentration studied 353 
(125 μM) was the most effective, this concentration, considering that a major part of 354 
ingested LF survives passage through the gut (Troost et al., 2001), would represent an 355 
unreasonable daily intake of milk or dairy products. Therefore, 12.5 μM LF was chosen 356 
for the subsequent experiments. 357 
Cell viability usually results from the balance between cell growth/proliferation 358 
and cell death. Also, cell death can occur by one of two different mechanisms, namely 359 
necrosis and/or apoptosis (Werner et al., 2005). Cells undergoing apoptosis are 360 
characterized by cell shrinkage, chromatin condensation, DNA fragmentation and 361 
membrane disassembling (Hakansson et al., 1995; Mader et al., 2005). Two main 362 
pathways have been reported to mediate apoptosis (Mader et al., 2005). One is the death 363 
receptor pathway which is triggered by ligand-inducing aggregation of death receptors, 364 
such as the Fas protein (Fujita et al, 2004). The second pathway is related with the 365 
activation of mitochondria response to cytotoxic drug-induced cellular stress (Mader et 366 
al., 2005). The results clearly showed an effect of LF in the apoptotic levels based on 367 
the activities of caspase 3 and 7 (effectors of the apoptosis machinery), and confirmed 368 
the cellular lysis occurring for the 72 hours of exposure to the higher protein 369 
concentration used. According to Sakai and coworkers (2005), pepsin-digested bovine 370 
LF influences the apoptosis machinery by activating the JK-SAPK signalling pathway 371 
in human oral squamous cell carcinoma cell line SAS. The authors found that treatment 372 
with pepsin-digested bovine LF induced cell death with apoptotic nuclear changes 373 
preceded by the cleavage of caspase-3 and poly (ADP-ribose) polymerase (PARP) in 374 
the apoptotic cells. Moreover, the peptide induced phosphorylation of extracellular 375 
signal-regulated kinase (ERK1/2), a member of the MAP kinase family, at early stages 376 
of apoptosis. Another MAP kinase, c-Jun N-terminal kinase/stress-activated protein 377 
kinase (JNK/SAPK), was also phosphorylated by treatment with pepsin-digested LF. 378 
Also, other authors (Hakansson et al., 1995; Roy et al., 2002) reported that LF and 379 
related compounds induce the genetic expression of Fas (Fujita et al., 2004), which is 380 
involved in apoptosis triggering. Roy and collaborators determined the effects of LF and 381 
several protein hydrolysates on the growth of human myeloid leukemic cells (HL-60). 382 
In their studies they showed that bovine milk contains biochemical factors with potent 383 
cytotoxic properties against some tumor cells and, that the key factors are mostly 384 
inactive within the structure of the precursor compounds, but can be released by 385 
enzymatic proteolysis. Also, a report from Tomita and collaborators (1994) provided 386 
evidence of in vivo production of lactoferricin B by isolating the peptide from the 387 
gastrointestinal contents of rats fed a diet containing bovine LF. Based on these 388 
evidences, it is likely that the activity of LF in apoptosis and cell growth is due mostly 389 
to its major peptide (lactoferricin) and therefore, further studies to clarify the possible 390 
mechanisms involved, as well as if LF could be degraded and to what extent in the cells 391 
culture medium, are required.  392 
As mentioned previously, cell proliferation is also an important factor affecting 393 
cell viability. As expected from the cell viability tests and apoptosis study, proliferation 394 
rates were found to decrease for both cell lines when exposed to LF, being this effect 395 
more pronounced for T47D. According to Xiao and coworkers (2004), LF has an effect 396 
in the cell cycle machinery, by influencing the genetic expression of some of its key 397 
components. LF is known to apprehend cancer cells in the G1-phase or alternatively 398 
forcing them to enter the latency phase G0-phase (Ward et al., 2005). The cell cycle 399 
machinery is mainly regulated by cyclin-dependent kinases (cdks) that are responsible 400 
for the progression through the cell cycle phases (Damiens et al., 1999). In addition, the 401 
retinoblastoma protein (pRb) is known to inhibit the cycle progression, although it is 402 
frequently phosphorylated by cdks, causing its loss of functionality (Damiens et al., 403 
1999). The mechanism by which LF inhibits cell proliferation may be related with the 404 
fact that it inhibits cdks and cyclin E genetic expression (Xiao et al., 2004). 405 
Furthermore, LF has been reported to increase the expression of pRb, p21 and p27, 406 
known as inhibitors of the cell cycle (Rodrigues et al., 2009; Damiens et al., 1999). 407 
Also, it is important to notice that LF possesses an estrogen response element (ERE) in 408 
its gene. The ERE is probably a key component for the anti-proliferation effect of LF, as 409 
it confers LF the ability to interfere in genetic expression (Stokes et al., 2004). 410 
According to Baumrucker and collaborators (2000), LF also affects the cell growth by 411 
interacting with epidermal growth factor binding protein 3 (EGFBP3). EGFBP3 usually 412 
binds with the epidermal growth factor (EGF), exerting a protective effect, thus helping 413 
cellular growth. Competing with EGF by EGFBP3, LF prevents the stimulation of cell 414 
growth. In spite of the information gathered in this preliminary study, further research 415 
should be conducted to determine the expression of cell cycle regulatory proteins as a 416 
starting point to disclose the mechanisms by which LF exerts its effect in cell 417 
proliferation. When a cancer has developed, it is beneficial that food components can 418 
slow the rate of tumor growth; therefore LF effect on cell growth rates should be 419 
assessed as well as a long-term treatment, since the daily intake of milk and dairy 420 
products might not be enough to produce an immediate physiological relevant dose 421 
(Freiburghaus et al., 2009).   422 
Cell migration is a key mechanism in the development of metastasis and tissue 423 
invasion. Therefore, any agent that can impair cell migration will yield a positive 424 
response in cancer treatment and recurrence. Fig. 3 and 4 showed that LF decreases the 425 
migration of both cell lines used, even for HS578T cells (Fig. 3) that have a higher 426 
migration potential (mainly due to the lack of estrogen receptor expression (ER-)) as 427 
compared to T47D (Fig. 4) for which the effect was more pronounced. This may be 428 
related with the fact that LF interacts with cadherins and integrins (Von Schlippe et al., 429 
2000), which in part can explain some cell detachment that occurred for T47D cells. 430 
Although these results would be more relevant if a greater effect had been observed for 431 
HS578T cells, as these are ER- and correspond to more aggressive type of tumors for 432 
which the existent therapy is not very efficient, this study is one of the first assessments 433 
on the effect of LF in migration (Giacontti, 2006; Neve et al., 2006; Ariazi et al., 2002). 434 
Moreover, the results obtained for T47D suggest that a combination of estrogen and LF 435 
could be further explored for breast cancer therapeutics.  436 
Although further research on the LF effects on breast cancer is required, the 437 
findings of this study are very promising, and of particular relevance for the food 438 
industry in general. The intake of milk and dairy products, or even food products 439 
enriched with LF, may be in the future a natural way of preventing breast cancer or 440 
enhancing patients’ treatment. 441 
 442 
CONCLUSIONS 443 
 444 
In conclusion, from the results gathered in this work it was found that a 48 h exposure 445 
to 12.5 μM LF decreases cell viability and proliferation for both cell lines studied. 446 
Furthermore, these conditions promoted an increase in apoptosis. Although the 447 
mechanisms of LF action are still not fully understood, there is evidence pointing to its 448 
ability to interact with some receptors, as well as to modulate genetic expression of 449 
several molecules that are vital to the cell cycle and apoptosis machinery. Moreover, LF 450 
was shown to decrease the ability of both cell lines to migrate. LF has a great potential 451 
to be used in breast cancer treatment. 452 
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566 
  567 
Table 1. Effect of LF treatment (0.125, 6.25, 12.5 and 125 μM) on HS578T and T47D 568 
cells for different exposure times (24, 48 and 72 h), by two complementary tests: TB 
569 
dye method and the bio-reduction of the MTS reagent. For both cell lines and tests, the 
570 
number of viable cells after treatment with PBS (no LF added) as control for each 
571 
exposure time was set at 100%. Results represent the percentage of viable cells for each 
572 
condition. Means (± standard deviation) were calculated from 3 independent cultures 
573 
and 8 measures for each culture. Significant changes to control: *: p < 0.05; **: p < 574 
0.005; ***: p < 0.0005 (two-tailed unpaired Student’s t-test). 575 
  
576 
Trypan Blue Method 
[LF] 
μM 
HS578T T47D 
24 h 48 h 72 h 24 h 48 h 72 h 
0.125 92.9 ± 6.0 * 91.6 ± 3.9 ** 41.6 ± 8.6 ** 95.6 ± 5.2 * 93.4 ± 5.2 97.9 ± 5.7 
6.25 75.4 ± 7.3 * 75.5 ± 4.0*** 54.1 ± 5.9 ** 78.5 ± 2.4 ** 69.5 ± 2.4*** 59.3 ± 3.1*** 
12.5 69.1 ± 3.7*** 81.9 ± 9.2 * 53.1 ± 6.3 ** 72.4 ± 7.3 ** 59.1 ± 7.3*** 46.3 ± 1.7*** 
125 40.6 ± 5.8*** 45.4 ± 4.9*** 13.6 ± 2.5*** 43.2 ± 8.6 ** 41.6 ± 8.6** 18.1 ± 3.6*** 
MTS Method 
[LF] 
μM 
HS578T T47D 
24 h 48 h 72 h 24 h 48 h 72 h 
0.125 88.5 ± 5.3 * 77.1 ± 3.7*** 30.2 ± 4.1*** 82.3 ± 4.3 ** 53.9 ± 2.7 ** 28.4 ± 3.2*** 
6.25 60.6 ± 4.1 ** 50.3 ± 1.9*** 4.5 ± 3.3 *** 75.3 ± 3.2*** 40.9 ± 4.3*** 11.3 ± 2.9*** 
12.5 67.8 ± 2.2*** 39.5 ± 2.2*** 17.5 ± 7.1*** 63.7 ± 5.1 ** 32.4 ± 5.3*** 8.2 ± 2.3 ***  
125 25.7 ± 3.5*** 13.3 ± 4.4*** 0.1 ± 3.2 *** 47.3 ± 2.6*** 21.3 ± 4.2*** 7.3 ± 4.1 *** 
 
577 
 
578 
 
579 
 
580 
 
581 
 
582 
 
583 
 
584 
 
585 
 
586 
 
587 
 
588 
 
589 
 
590 
 
591 
 
592 
FIGURE CAPTIONS 
593 
 
594 
Figure 1. Apoptosis: effect of LF treatment (0.125, 6.25, 12.5 and 125 μM) on: (A) 595 
HS578T and (B) T47D apoptosis levels for different exposure times (24, 48 and 72 h). 
596 
Results represent an average of 3 independent cultures and 8 measures for each culture. 
597 
Significant changes to control: *: p < 0.05; **: p < 0.005; ***: p < 0.0005 (two-tailed 598 
unpaired Student’s t-test). 
599 
 
600 
Figure 2. Cell proliferation: effect of LF treatment (12.5 μM; 48 h exposure). Control 601 
samples (with no LF added) were included for both cell lines. T47D: Control samples: 
602 
(A) - total nuclei, (B) - nuclei in proliferation; Treated samples: (C) - total nuclei, (D) - 
603 
nuclei in proliferation. HS578T: Control samples: (E) - total nuclei, (F) - nuclei in 
604 
proliferation; Treated samples: (G) - total nuclei, (H) - nuclei in proliferation. 
605 
Magnification used: 40X. Scale bar 10 μm. 606 
 
607 
Figure 3. Migration: effect of LF treatment (12.5 μM; 48 h exposure) on HS578T cells. 608 
Exposure time to LF: 0 h - (A); exposure time to LF: 48 h – (B). Table summarizes the 
609 
distances (μm) over time between the front cells in each edge of the wound and the 610 
results represent an average of 3 independent cultures and 9 measures for each culture. 
611 
Control samples (with no LF added) were included. Magnification used: 40X. Scale bar 
612 
10 μm. 613 
 
614 
Figure 4. Migration: effect of LF treatment (12.5 μM; 48 h exposure) on T47D cells. 615 
Exposure time to LF: 0 h - (A); exposure time to LF: 48 h – (B). Table summarizes the 
616 
distances (μm) over time between the front cells in each edge of the wound and the 617 
results represent an average of 3 independent cultures and 9 measures for each culture. 
618 
Control samples (with no LF added) were included. Magnification used: 40X. Scale bar 
619 
10 μm. 620 
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 [Distance μm] 
Time (h) 0 μM LF 12.5 μM LF 
0 179 ± 2 167 ± 3 
3 172 ± 1 162 ± 3 
6 100 ± 3 116 ± 4 
9 98 ± 2 109 ± 1 
24 72 ± 3 82 ± 6 
27 50 ± 12 48 ± 2 
30 20 ± 10 27 ± 2 
34 13 ± 6 26 ± 4 
48 0 ± 1 6 ± 3 
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Figure 3.  
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  672 
A B 
 
673 
 
674 
 [Distance μm] 
Time (h) 0 μM LF 12.5 μM LF 
0 382 ± 8 380 ± 3 
3 372 ± 19 379 ± 2 
6 257 ± 14 366 ± 3 
9 222 ± 12 373 ± 9 
24 166 ± 12 380 ± 10 
27 116 ± 13 390 ± 6 
30 103 ± 9 377 ± 6 
34 87 ± 5 377 ± 4 
48 87 ± 5 386 ± 4 
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